174 related articles for article (PubMed ID: 36732658)
1. The E3 ligase RBCK1 reduces the sensitivity of ccRCC to sunitinib through the ANKRD35-MITD1-ANXA1 axis.
Wang Y; Peng M; Zhong Y; Xiong W; Zhu L; Jin X
Oncogene; 2023 Mar; 42(13):952-966. PubMed ID: 36732658
[TBL] [Abstract][Full Text] [Related]
2. YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway.
Li W; Ye K; Li X; Liu X; Peng M; Chen F; Xiong W; Wang Y; Zhu L
J Exp Clin Cancer Res; 2022 Aug; 41(1):250. PubMed ID: 35974388
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
Front Immunol; 2021; 12():734646. PubMed ID: 34795663
[TBL] [Abstract][Full Text] [Related]
4. Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation.
Marona P; Górka J; Kwapisz O; Jura J; Rys J; Hoffman RM; Miekus K
Cell Death Dis; 2022 Sep; 13(9):814. PubMed ID: 36138026
[TBL] [Abstract][Full Text] [Related]
5. Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma.
Ruan H; Li S; Bao L; Zhang X
Oncogene; 2020 Sep; 39(38):6113-6128. PubMed ID: 32814829
[TBL] [Abstract][Full Text] [Related]
6. ZDHHC2-Mediated AGK Palmitoylation Activates AKT-mTOR Signaling to Reduce Sunitinib Sensitivity in Renal Cell Carcinoma.
Sun Y; Zhu L; Liu P; Zhang H; Guo F; Jin X
Cancer Res; 2023 Jun; 83(12):2034-2051. PubMed ID: 37078777
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma.
Hwang HS; Go H; Park JM; Yoon SY; Lee JL; Jeong SU; Cho YM
Lab Invest; 2019 May; 99(5):659-670. PubMed ID: 30683903
[TBL] [Abstract][Full Text] [Related]
8. CD276 enhances sunitinib resistance in clear cell renal cell carcinoma by promoting DNA damage repair and activation of FAK-MAPK signaling pathway.
Zhang ZY; Xu JH; Zhang JL; Lin YX; Ou-Yang J
BMC Cancer; 2024 May; 24(1):650. PubMed ID: 38802739
[TBL] [Abstract][Full Text] [Related]
9. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
10. Gas6-Axl signaling in presence of Sunitinib is enhanced, diversified and sustained in renal tumor cells, resulting in tumor-progressive advantages.
Gustafsson A; Fritz HKM; Dahlbäck B
Exp Cell Res; 2017 Jun; 355(1):47-56. PubMed ID: 28327411
[TBL] [Abstract][Full Text] [Related]
11. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma.
Makhov P; Sohn JA; Serebriiskii IG; Fazliyeva R; Khazak V; Boumber Y; Uzzo RG; Kolenko VM
Br J Cancer; 2020 Dec; 123(12):1749-1756. PubMed ID: 32968206
[TBL] [Abstract][Full Text] [Related]
13. ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma.
Zhu L; Ding R; Yan H; Zhang J; Lin Z
Cell Death Dis; 2020 May; 11(5):337. PubMed ID: 32382017
[TBL] [Abstract][Full Text] [Related]
14. TFE3-PD-L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma.
Guo X; Li R; Bai Q; Jiang S; Wang H
J Cell Mol Med; 2020 Dec; 24(24):14441-14452. PubMed ID: 33145941
[TBL] [Abstract][Full Text] [Related]
15. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
[TBL] [Abstract][Full Text] [Related]
16. CircME1 promotes aerobic glycolysis and sunitinib resistance of clear cell renal cell carcinoma through cis-regulation of ME1.
Zhang MX; Wang JL; Mo CQ; Mao XP; Feng ZH; Li JY; Lin HS; Song HD; Xu QH; Wang YH; Lu J; Wei JH; Han H; Chen W; Mao HP; Luo JH; Chen ZH
Oncogene; 2022 Aug; 41(33):3979-3990. PubMed ID: 35798876
[TBL] [Abstract][Full Text] [Related]
17. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
[No Abstract] [Full Text] [Related]
18. Risk signature identification and NPRL2 affects sunitinib sensitivity in clear cell renal cell carcinoma.
Du X; Zhao Z; Zhao X; Wang H; Jiang L; Tang W
Biochem Biophys Res Commun; 2023 Jun; 663():122-131. PubMed ID: 37121122
[TBL] [Abstract][Full Text] [Related]
19. ARRDC3 regulates the targeted therapy sensitivity of clear cell renal cell carcinoma by promoting AXL degradation.
Chen M; Yin B; Liu Y; Li M; Shen S; Wu J; Li W; Fan J
Cell Cycle; 2024 Jan; 23(1):56-69. PubMed ID: 38389126
[TBL] [Abstract][Full Text] [Related]
20. RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma.
Yu S; Dai J; Ma M; Xu T; Kong Y; Cui C; Chi Z; Si L; Tang H; Yang L; Sheng X; Guo J
Cell Death Dis; 2019 Mar; 10(4):254. PubMed ID: 30874541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
